Carna Biosciences
Japanese drug-discovery company focused on kinase-inhibitor small-molecule pharmaceuticals, also supplying kinase research products and contract services.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Carna Biosciences, Inc. (カルナバイオサイエンス株式会社) is a Japanese company whose business consists of drug discovery (research and development of kinase inhibitors and other small-molecule pharmaceuticals) and drug-discovery support (provision of products and contract services related to kinase-inhibitor drug-discovery research). It states that it provides kinase proteins manufactured entirely in-house, from all products and all processes, and that it has earned high trust in the kinase drug-discovery field through its accumulated experience and know-how. Its stated corporate philosophy is to protect people's lives and contribute to health, aiming to provide effective drugs in areas of high unmet medical need. The company name Carna derives from the Roman goddess who protects human health. It has a subsidiary, CarnaBio USA, Inc., located in Natick, Massachusetts, USA.
History
Carna Biosciences, Inc. was established on April 10, 2003. Its corporate philosophy is to protect people's lives and contribute to health, and it pursues research and development of innovative pharmaceuticals that can contribute to patients suffering from disease worldwide, focusing on small-molecule pharmaceuticals such as kinase inhibitors. It also provides products and services necessary for the creation of new kinase inhibitors to pharmaceutical companies and research institutions. The company name 'Carna' comes from the Roman goddess who protects human health. As of December 31, 2025, the company had 61 consolidated employees. It has a subsidiary, CarnaBio USA, Inc., based in Natick, Massachusetts, USA, which handles drug-discovery support and drug-discovery businesses in North America.
Products and positioning
Focused on kinase-inhibitor small-molecule pharmaceuticals and on supporting kinase drug-discovery research with high-quality products and services.
Kinase proteins
Contract services for kinase drug-discovery research
Recent events
Brickell Biotech acquires exclusive rights to Carna Biosciences’ autoimmune drug portfolio[6]
Reported:
Brickell Biotech announced that it acquired exclusive rights to develop and commercialize a portfolio of autoimmune drugs created by Carna Biosciences.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/carna-biosciences · Editorial policy · How profiles are compiled